Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds RSS Feed PharmiWeb Candidate Blog RSS Feed PharmiWeb Client Blog


Press Release

Osteosarcoma Pipeline Review, H2 2016 - 20 Companies & 41 Molecules - Research and Markets

Research and Markets
Posted on: 20 Sep 16

Research and Markets has announced the addition of the "Osteosarcoma - Pipeline Review, H2 2016" report to their offering.

The report provides comprehensive information on the therapeutics under development for Osteosarcoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Osteosarcoma and features dormant and discontinued projects.

Osteosarcoma is the most common cancer of the bone that destroys tissue and weakens the bone. It is developed from immature bone cells that normally form new bone tissue. Symptoms include pain, bone fractures, swelling, redness and limitation of motion of joints. Risk factors include age, gender, family history and Li-Fraumeni syndrome. Treatment includes chemotherapy and surgery.

Osteosarcoma pipeline therapeutics constitutes close to 41 molecules. Out of which approximately 26 molecules are developed by Companies and remaining by the Universities/Institutes. The molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 12, 5, 7 and 2 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 4, 3, 3 and 5 molecules, respectively.

Key Topics Covered:

  1. Introduction
  2. Osteosarcoma Overview
  3. Therapeutics Development
  4. Pipeline Products for Osteosarcoma - Overview
  5. Pipeline Products for Osteosarcoma - Comparative Analysis
  6. Osteosarcoma - Therapeutics under Development by Companies
  7. Osteosarcoma - Therapeutics under Investigation by Universities/Institutes
  8. Osteosarcoma Products Glance
  9. Late Stage Products
  10. Clinical Stage Products
  11. Early Stage Products
  12. Osteosarcoma - Products under Development by Companies
  13. Osteosarcoma - Products under Investigation by Universities/Institutes
  14. Osteosarcoma - Companies Involved in Therapeutics Development
  • Advaxis, Inc.
  • Amgen Inc.
  • AVEO Pharmaceuticals, Inc.
  • Bayer AG
  • Bellicum Pharmaceuticals, Inc.
  • Celldex Therapeutics, Inc.
  • CytRx Corporation
  • Eleison Pharmaceuticals LLC
  • Exelixis, Inc.
  • Isofol Medical AB
  • MediaPharma s.r.l.
  • Merck & Co., Inc.
  • Merrimack Pharmaceuticals, Inc.
  • Netris Pharma S.A.S.
  • Novartis AG
  • Oncolys BioPharma Inc
  • Pfizer Inc.
  • Shionogi & Co., Ltd.
  • Teijin Pharma Limited
  • United Therapeutics Corporation

For more information about this report visit

Related Topics: Oncology Drugs

View source version on

Business Wire

Last updated on: 20/09/2016

Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.